Novavax, Inc. (NVAX) News

Novavax, Inc. (NVAX): $5.76

-0.02 (-0.35%)

POWR Rating

Component Grades













Add NVAX to Watchlist
Sign Up

Industry: Biotech


of 383

in industry

Filter NVAX News Items

NVAX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NVAX News Highlights

  • NVAX's 30 day story count now stands at 20.
  • Over the past 17 days, the trend for NVAX's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • DRUG, BASE and FCF are the most mentioned tickers in articles about NVAX.

Latest NVAX News From Around the Web

Below are the latest news stories about NOVAVAX INC that investors may wish to consider to help them evaluate NVAX as an investment opportunity.

1 Green Flag and 1 Red Flag for Novavax

Novavax (NASDAQ: NVAX) has had more than its share of ups and downs over the past few years -- and investors have been along for the ride. The stock soared 2,700% in 2020 as the company brought its coronavirus vaccine candidate through late-stage clinical trials. The biotech company's vaccine reached commercialization later than rivals.

Yahoo | March 18, 2023

Novavax (NVAX) Gains But Lags Market: What You Should Know

Novavax (NVAX) closed at $5.97 in the latest trading session, marking a +1.19% move from the prior day.

Yahoo | March 16, 2023

Is Novavax Stock A Sell After Expressing 'Substantial Doubt' About Its Future?

Is Novavax stock a sell after the company says it has "substantial doubt" about its future? Is NVAX stock a sell right now?

Yahoo | March 16, 2023

2 Growth Stocks That Are Trading at a Huge Discount Right Now -- Maybe Rightfully So

On that note, here are a couple of severely beaten-down growth stocks that are popular among investors, but only one of them has a credible path to stay in business. With ambitions to become the world's biggest seller of legal cannabis products, Tilray Brands (NASDAQ: TLRY) is also a growth stock that's remarkably inexpensive. Despite reporting $144 million in revenue for its fiscal second quarter and free cash flow (FCF) of $25.4 million, its shares are down 42.7% in the last three years because of persistent unprofitability and wild oversupply compared to demand across several continents.

Yahoo | March 16, 2023

3 Vaccine Stocks to Watch for Their Post-Pandemic Moves

The vaccine stocks Pfizer, Moderna, and Novavax all have approved Covid-19 vaccines.

John Blankenhorn on InvestorPlace | March 15, 2023

This Growth Stock Is Down 90%. Is It Time to Sell or Buy?

In light of the pessimistic messaging from its management and the low expectations that professional analysts have for it over the next couple of years, shareholders now face the prospect of the company's potential collapse. The crux of Novavax's problem is that its coronavirus vaccines were approved too late to gain a significant share of the global market, which competitors like Pfizer and Moderna cornered quite rapidly thanks to favorable receptions from regulators and sufficient manufacturing capacity to meet demand on a reasonable timetable. Due to a series of mishaps with its manufacturing operations, Novavax's Nuvaxovid jab didn't get an Emergency Use Authorization (EUA) from the Food and Drug Administration until mid-July 2022 -- almost two years later than Pfizer's vaccine go...

Yahoo | March 12, 2023

1 Stock You Need to Sell Before the Next Bull Market

Despite the long-lived loyalty of Novavax's (NASDAQ: NVAX) boisterous base of retail investors called the "Nova-stans," the company's seemingly endless struggles appear poised to burden it to the point of collapse. While it's faintly possible that the biotech will survive, investors shouldn't stick around to find out, and it's probably also time to do some soul-searching about the merits of deciding to become one of its shareholders in the first place. At the moment, Novavax has a gnarly complex of problems that it has no way of solving.

Yahoo | March 11, 2023

Novavax Stock: Bear vs. Bull

Novavax (NASDAQ: NVAX) has a track record of major gains and major losses within the past few years. Novavax shares have dropped a mind-boggling 97% from their peak. Considering all of this, should you buy Novavax or avoid the stock?

Yahoo | March 10, 2023

Novavax Just Dropped a Bombshell on Investors: Even Management Is Questioning Its Future

Novavax (NASDAQ: NVAX) faces an uncertain future ahead as the need for COVID-19 vaccines diminishes. The situation is so bad that even management issued a warning on its latest quarterly earnings report. Last month, Novavax released its year-end results.

Yahoo | March 8, 2023

Novavax to Participate in TD Cowen's 43rd Annual Health Care Conference

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in TD Cowen's 43rd Annual Health Care Conference.

Yahoo | March 6, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.66 seconds.